查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679410

前列腺癌治疗市场规模、份额、趋势分析报告：按药物类别、分销管道、地区和细分市场预测，2025-2030 年

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

前列腺癌治疗市场的成长和趋势

根据 Grand View Research, Inc. 的一份新报告，到 2030 年全球前列腺癌治疗市场规模预计将达到 220 亿美元。

预计 2025 年至 2030 年间，市场复合年增长率将达到 8.6%。该市场的成长是由于前列腺癌发生率的上升，从而增加了对新型治疗方法的需求。例如，根据ACS预测，2022年全球将新增268,490例前列腺癌病例，并有34,500例死亡病例。大约每 8 名男性中就有 1 名在一生中的某个阶段患有前列腺癌，并且在老年男性中更为常见。

政府资金的激增、公共和私营部门为提高知识水平而采取的倡议的增加以及公众对药品供应的认识不断提高，预计将推动市场成长。此外，与传统方式相比，人们越来越偏好透过网路购买药品，网路使用者数量不断增加，以及人们对网路药局的认识不断提高，预计治疗采用率将有所提高。

根据美国癌症协会的数据，2022 年，摄护腺癌是美国男性人口的第二大死因，大约每 41 名男性中就有 1 名死于摄护腺癌。儘管前列腺癌是一种致命的疾病，但疾病的死亡率很低。有利的监管环境预计将促进 177Lu-PSMA-617 等新产品的采用，177Lu-PSMA-617 是一种针对多种疗法无法治癒的患者的精准药物。本产品于2022年3月获得FDA核准，用于治疗mCRPC。

标靶治疗、生物治疗、化疗和荷尔蒙疗法是治疗疾病的一些方法。标靶治疗和其他免疫疗法的高成本预计将成为全球市场的一个主要限制。在新兴市场，对治疗领域技术进步的认识较低预计将对市场造成限制。

伦敦大学学院 MRC 临床试验部等研究机构正在进行新的临床试验。根据该实验室于 2022 年 6 月发表的一篇论文，多西他赛等化疗已被证明对继发性前列腺癌患者有效，可将存活率提高 39%。这些研究为前列腺癌患者提供了个人化的医疗方法，产生了更有效且副作用更少的方法。

前列腺癌治疗市场报告重点

  • 根据药物类别，荷尔蒙疗法将占据最大的份额，并且由于其可用性和有效的作用机制可以完全治疗疾病，预计将快速增长。
  • 由于该药物的高采用率和长期使用，Xtandi 预计将在预测期内以最快的速度成长。
  • 预计北美将在 2024 年占据市场主导地位，并有望成为成长最快的地区，因为该地区前列腺癌的盛行率不断上升，并且对前列腺癌治疗产品的需求强劲。
  • 在这个市场中运作的主要企业正专注于开发新产品以满足需求并提供有效的治疗选择。

目录

第一章调查方法与范围

第二章执行摘要

3. 前列腺癌治疗市场变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析

4.前列腺癌治疗市场：药物类别业务分析

  • 2024 年及 2030 年药品类别市场占有率
  • 药品类别细分仪表板
  • 2018 年至 2030 年药品类别市场规模、预测与趋势分析
  • 荷尔蒙疗法
  • 化疗
  • 免疫疗法
  • 标靶治疗
  • 其他的

第五章前列腺癌治疗市场：通路业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 2018 年至 2030 年分销通路市场规模、预测与趋势分析
  • 医院药房
  • 药局和药房
  • 网路药局

第六章前列腺癌治疗市场：按地区估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年各国情况
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 2018-2030年各国情况
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018-2030年各国情况
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030年各国情况
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Johnson & Johnson Services, Inc.
    • Astellas Pharma Inc.
    • Eli Lilly and Company
    • Sanofi
    • Ipsen Pharma
    • Bayer AG
    • AstraZeneca
    • Bausch Health Companies Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
Product Code: GVR-1-68038-925-8

Prostate Cancer Therapeutics Market Growth & Trends:

The global prostate cancer therapeutics market size is expected to reach USD 22.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.6% from 2025 to 2030. The growth of the market is attributed to the escalating prevalence of prostate cancer which in turn increases the demand for novel therapeutics. For instance, as per the ACS in 2022, prostate cancer is expected to have 268,490 new cases and lead to the death of 34,500 people worldwide. It affects roughly one out of every eight men at some point in their lives and is more common in older men.

A surge in government funding and increased public and private sector initiatives to enhance knowledge, and awareness about the availability of medicines amongst the public are projected to accelerate market growth. Furthermore, a rising preference for online drug purchasing over traditional methods, an increase in the number of internet users, and a rise in awareness regarding online pharmacies are expected to enhance the treatment adoption rate.

As per the American Cancer Society, in 2022, prostate cancer is the second leading cause of death in the male population of the U.S. Around one man in every 41 dies from prostate cancer. Although prostate cancer is a deadly disease, the mortality rate from the disease is low. The availability of a supportive regulatory landscape is expected to drive the adoption of novel products such as 177Lu-PSMA-617, which is precision medicine for patients that have not been cured with multiple rounds of treatment. The product received FDA approval in March 2022 for the treatment of mCRPC.

Targeted and biological therapy, chemotherapy, and hormonal therapy are some of the methods used to treat the condition. The high cost of targeted therapies and other immunotherapies is projected to act as a significant limitation on the global market. Low awareness of technological advancements in the therapeutic area in developing countries is expected to become a restrain for the market.

New trials are being conducted by institutes such as MRC Clinical Trials Unit at UCL. A June 2022, publication by the institute highlights secondary cancer tumor type of prostate cancer patients are benefited more from the use of chemotherapy such as docetaxel with an enhanced survival rate of 39%. These studies are creating a more effective way of providing a personalized medicine approach to prostate cancer patients so that they experience fewer side effects.

Prostate Cancer Therapeutics Market Report Highlights:

  • By drug class, the hormonal therapy segment held the largest share and is expected to be the fastest-growing segment due to the availability and efficient mechanism of action for treating the diseased condition completely
  • Xtandi drug is expected to grow at the fastest rate over the forecast period due to the high adoption of the drug and usage of the drug for longer periods of time
  • North America dominated the market in 2024 and is anticipated to be the fastest-growing region owing to an increase in the disease's prevalence, and a strong need for prostate cancer therapeutic products in the region
  • Key market players operating in the market are focusing on developing novel products to meet the demand and provide efficient treatment options

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Prostate Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Prostate Cancer Therapeutics Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Hormonal Therapy
    • 4.4.1. Hormonal Therapy Market, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Targeted Therapy
    • 4.7.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Prostate Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Drug Stores & Retail Pharmacies
    • 5.5.1. Drug Stores & Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6. Prostate Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Prostate Cancer Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Johnson & Johnson Services, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Astellas Pharma Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Eli Lilly and Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Ipsen Pharma
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bayer AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Bausch Health Companies Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Merck & Co., Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Pfizer Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global prostate cancer therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 North America prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 North America prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 US prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 US prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 12 Canada prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Mexico prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 UK prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 UK prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Germany prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Italy prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Italy prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Spain prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Spain prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Norway prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Norway prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Denmark prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 31 Denmark prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Sweden prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Japan prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Japan prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 China prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 China prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 India prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 India prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Australia prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Australia prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 South Korea prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 South Korea prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Thailand prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Latin America prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 Brazil prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Argentina prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa prostate cancer therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 South Africa prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 UAE prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 UAE prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait prostate cancer therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait prostate cancer therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Prostate Cancer Therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class and distribution channel outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Prostate cancer therapeutics market dynamics
  • Fig. 12 Prostate cancer therapeutics market: Porter's five forces analysis
  • Fig. 13 Prostate cancer therapeutics market: PESTLE analysis
  • Fig. 14 Prostate cancer therapeutics market: Drug class segment dashboard
  • Fig. 15 Prostate cancer therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 16 Hormonal therapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Others market, 2018 - 2030 (USD Million)
  • Fig. 21 Prostate cancer therapeutics market: Distribution channel segment dashboard
  • Fig. 22 Prostate cancer therapeutics market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 23 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 24 Drug stores & retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 25 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 26 Prostate cancer therapeutics market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 41 France country dynamics
  • Fig. 42 France prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 China country dynamics
  • Fig. 57 China prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 India country dynamics
  • Fig. 59 India prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 MEA prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait prostate cancer therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework